Clinical Research Directory
Browse clinical research sites, groups, and studies.
Edge AI Neurostimulation Controllers Versus Continuous Therapy for Drug-Resistant Focal Epilepsy
Sponsor: Lahore Medical and Dental College
Summary
Drug-resistant focal epilepsy remains a major therapeutic challenge. Conventional neurostimulators rely on static, continuous open-loop stimulation or low-bandwidth reactive loops that suffer from classification latency or high battery consumption. This prospective, double-blind, randomized controlled trial evaluates whether hardware-integrated edge computing artificial intelligence (AI) neurostimulators demonstrate superior seizure reduction, lower processing latency, and reduced battery drain compared to standard continuous neurostimulation therapy over a 6-week intervention period.
Official title: Edge Computing Artificial Intelligence Neurostimulation Controllers Versus Standard Continuous Therapy for Drug Resistant Focal Epilepsy: A Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2023-06-01
Completion Date
2024-01-01
Last Updated
2026-11-03
Healthy Volunteers
No
Conditions
Interventions
Edge AI Neurostimulator Controller
Hardware-integrated neural processing engine executing real-time feature extraction and pre-ictal spike classification from intracranial EEG, triggering adaptive electrical bursts.
Continuous Open-Loop Neurostimulator
Static, fixed-frequency continuous open-loop electrical pulse stimulation delivered regardless of underlying electrical activity.
Locations (1)
Tertiary Neurosurgical Referral Hospitals
Lahore, Punjab Province, Pakistan